These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 16443423)

  • 1. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation.
    Reuben DB; Palla SL; Hu P; Reboussin BA; Crandall C; Herrington DM; Barrett-Connor E; Greendale GA
    Am J Med; 2006 Feb; 119(2):167.e1-8. PubMed ID: 16443423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
    Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
    J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.
    Lakoski SG; Herrington DM
    Climacteric; 2005 Dec; 8(4):317-26. PubMed ID: 16390766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin.
    Miller VT; Muesing RA; LaRosa JC; Stoy DB; Fowler SE; Stillman RJ
    Obstet Gynecol; 1994 Feb; 83(2):173-9. PubMed ID: 8290177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis.
    Heald A; Selby PL; White A; Gibson JM
    Am J Obstet Gynecol; 2000 Sep; 183(3):593-600. PubMed ID: 10992179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
    Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of progestins on estrogen-induced increase in C-reactive protein in postmenopausal women.
    Rossi R; Bursi F; Veronesi B; Cagnacci A; Modena MG
    Maturitas; 2004 Dec; 49(4):315-20. PubMed ID: 15531127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.
    Crandall CJ; Karlamangla A; Huang MH; Ursin G; Guan M; Greendale GA
    Arch Intern Med; 2006 Aug 14-28; 166(15):1578-84. PubMed ID: 16908790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women.
    Kiran H; Kiran G
    Arch Gynecol Obstet; 2006 Apr; 274(1):9-12. PubMed ID: 16369811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial.
    Hu P; Greendale GA; Palla SL; Reboussin BA; Herrington DM; Barrett-Connor E; Reuben DB
    Atherosclerosis; 2006 Apr; 185(2):347-52. PubMed ID: 16023653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
    Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN
    Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women.
    Carr BR; Khan N; Adams-Huet B; Kakarla N; Havelock JC; Gell J
    Fertil Steril; 2006 Mar; 85(3):667-73. PubMed ID: 16500336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial.
    Lakoski SG; Brosnihan B; Herrington DM
    Am Heart J; 2005 Nov; 150(5):907-11. PubMed ID: 16290959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of alcohol and cigarette smoking on change in serum estrone levels in postmenopausal women randomly assigned to fixed doses of conjugated equine estrogens with or without a progestin.
    McDivit AM; Greendale GA; Stanczyk FZ; Huang MH
    Menopause; 2008; 15(2):382-5. PubMed ID: 18000469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin.
    Xing S; Wu Y; Liu J; Xu R; Zhang Z; Wang Y
    Chin Med J (Engl); 2003 Apr; 116(4):584-7. PubMed ID: 12875727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen, progestogens and cardiovascular risk.
    Stefanick ML
    J Reprod Med; 1999 Feb; 44(2 Suppl):221-6. PubMed ID: 11392036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.